Biotechnology firm Pharming announced on Friday that its net loss in 2008 rose to €26m compared to €21m in the preceding year. Turnover remained stable at €700,000.

The company is planning to register its allergy drug Rhucin, one of its most promising products, for the European and US market this year.
In its statement, Pharming said it was unable to give a concrete forecast for 2009 given the uncertainties in the current economic climate.
‘The Pharming team is confident about the outlook for 2009. Together, we will execute and deliver on our key objectives; the strengthening of the product pipeline and our financial position, said CEO Sijmen de Vries.